The estimated Net Worth of Eugene D Rabe is at least $19.1 Million dollars as of 17 November 2004. Eugene Rabe owns over 50,000 units of Abiomed stock worth over $19,051,000 and over the last 21 years Eugene sold ABMD stock worth over $0.
Sign up
Eugene Rabe ABMD stock SEC Form 4 insiders trading
Eugene has made over 11 trades of the Abiomed stock since 2003, according to the Form 4 filled with the SEC. Most recently Eugene exercised 50,000 units of ABMD stock worth $329,500 on 17 November 2004.
The largest trade Eugene's ever made was exercising 50,000 units of Abiomed stock on 17 November 2004 worth over $329,500. On average, Eugene trades about 13,077 units every 29 days since 2003. As of 17 November 2004 Eugene still owns at least 50,000 units of Abiomed stock.
You can see the complete history of Eugene Rabe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eugene Rabe's mailing address?
Eugene's mailing address filed with the SEC is , , , , .
Insiders trading at Abiomed
Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose, and David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of Eugene Rabe stock trades at Abiomed
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director